← Pharma & APIs
Critical node· Pharma & APIs · Critical anchor
Viral vectors (gene therapy)
Oxford, United Kingdom51.75°N 1.26°W
computed criticality17/100
reading
Gene therapies depend on viral vectors (AAV, lentivirus) made by very few CDMOs: 5 leaders ≈ 1/3 of world capacity, ~50% in the US
2024Fault line
Correcting a gene requires a viral 'carrier' made under extreme purity, a scarce and costly capacity concentrated in a few CDMOs. The manufacturing bottleneck, more than the science, limits access to gene therapies.
Actors
Oxford Biomedica
Catalent
Thermo Fisher
Lonza
Sources